An estimated 230 million girls and women live with the consequences of FGM. Clinicians can help identify those affected or at ...
The FDA has granted accelerated approval to the kinase inhibitor neladalkib (Nelkarmi, Nuvalent) for adults with locally ...
Doctors Condemn Prediction Markets on Clinical Trial Outcomes, Warning of Threats to Trial Integrity
Kalshi's pilot lets users wager on late-stage trial results. Physicians and researchers say the markets threaten trial ...
Giredestrant plus everolimus significantly outperforms standard endocrine therapy in a post-CDK4/6 inhibitor setting.
Electroacupuncture reduced liver fat and partly restored anti-inflammatory macrophages in mice, offering early signs that ...
Study reports an AI model is as accurate as humans for generating preliminary echocardiogram interpretations, saving time for ...
By testing procedures, pathogens, and substances on themselves, these researchers generated discoveries that left a lasting ...
Patients can be left with nonmedical expenses that are substantial for them, but a drop in the bucket for trial sponsors.
Primary care practitioners report that using an AI scribe gives them back much-needed time that some use to see more patients ...
Women’s hormonal transitions remain underrepresented in neuroscience research, despite evidence linking changes in estrogen ...
An international panel reaches consensus on just 35 of 105 clinical statements on ketamine and esketamine, leaving key ...
A survey of nearly 29,000 healthcare workers in France highlights the effects of extreme weather on clinical care, staff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results